低或中风险性腺毒性化疗对青春期前男孩睾丸组织冷冻前后精原细胞数量的影响
该研究分析了79例青春期前癌症男孩在睾丸组织冷冻前接受低或中风险性腺毒性化疗后睾丸组织中精原细胞数量。结果显示,烷化剂显著降低精原细胞数量,长春新碱与烷化剂联用有额外不良影响,而卡铂单用未见独立贡献。作者建议对预测环磷酰胺等效剂量超过4000 mg/m2的化疗患者提议睾丸组织冷冻。
要点
- 烷化剂暴露男孩的平均S/T显著低于非烷化剂暴露男孩(P=0.018)。
- 长春新碱联合烷化剂使TFI进一步降低22.4%(P=0.0049),多因素分析校正CED后仍与长春新碱给药相关(P=0.02)。
- 卡铂作为唯一烷化剂与非烷化剂组相比,S/T无差异。
核心结论
- 在青春期前男孩睾丸组织中,长春新碱与烷化剂联用对精原细胞数量有额外不良影响,而卡铂对精原细胞数量无独立贡献。
- 作者建议对预测环磷酰胺等效剂量(CED)超过4000 mg/m2的化疗患者提议睾丸组织冷冻。
研究设计与样本
- 描述性研究,纳入79例诊断为癌症的青春期前男孩(6个月至16岁),睾丸组织样本于2009年5月至2014年6月间冷冻保存。
- 所有患者均在接受造血干细胞移植预处理前接受过低或中风险性腺毒性化疗,且化疗信息完整。
- 通过形态学和免疫组化分析评估精原细胞数量和睾丸组织质量。
主要发现
- 烷化剂暴露男孩的平均S/T显著低于非烷化剂暴露男孩(P=0.018)。
- 未接受烷化剂组S/T随年龄增加(r=0.6166,P=0.0434),接受CED公式中烷化剂组S/T随年龄减少(r=-0.3759,P=0.0036)。
- 接受长春新碱联合烷化剂组TFI和S/T进一步降低(TFI降低22.4%,P=0.0049;S/T P<0.0001),但该组CED也显著增加(P<0.0001)。
- 多因素分析校正CED后,TFI降低仍与长春新碱给药相关(P=0.02)。
- 卡铂作为唯一烷化剂与非烷化剂组相比,S/T无差异。
关键数值与推荐
- 法国国家癌症患者生育力保存指南推荐在高性腺毒性治疗前进行睾丸组织冷冻。
- 作者建议对预测CED超过4000 mg/m2的化疗患者提议睾丸组织冷冻。
- 长春新碱和卡铂的数据需在后续纳入更多患者的研究中确认。
临床怎么用
- 对于需要生育力保存的青春期前男孩,作者建议在预测CED超过4000 mg/m2的化疗前提议睾丸组织冷冻。
- 法国国家指南推荐在高性腺毒性治疗前进行睾丸组织冷冻。
- 长春新碱联合烷化剂对精原细胞数量的额外不良影响需在临床咨询中考虑。
局限性
- 本研究为描述性研究,睾丸组织来自有不育风险的青春期前男孩。
- 研究人群异质性较大,各亚组患者数量少。
- 结果基于接受烷化剂患者与接受非烷化剂患者的比较,而非与未接受化疗患者比较。
- 由于法国国家指南推荐在高性腺毒性治疗前进行睾丸组织冷冻,所有患者均在睾丸组织冷冻前接受过低或中风险性腺毒性化疗,无法获得化疗初治且癌症组织学类型可比患者的睾丸组织样本。
- 由于样本量有限,无法通过移植或体外成熟测试精原细胞和体细胞的功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the impact of low- or moderate-risk gonadotoxic chemotherapy received prior to testicular tissue freezing (TTF), and of the cancer itself, on spermatogonia quantity in testicular tissue from (pre)pubertal boys? SUMMARY ANSWER: Vincristine, when associated with alkylating agents, has an additional adverse effect on spermatogonia quantity, while carboplatin has no individual contribution to spermatogonia quantity, in testicular tissue of (pre)pubertal boys, when compared to patients who have received non-alkylating chemotherapy. WHAT IS KNOWN ALREADY: The improved survival rates after cancer treatment necessitate the inclusion of fertility preservation procedures as part of the comprehensive care for patients, taking into consideration their age. Sperm cryopreservation is an established procedure in post-pubertal males while the TTF proposed for (pre)pubertal boys remains experimental. Several studies exploring testicular tissue of (pre)pubertal boys after TTF have examined the tubular fertility index (TFI, percentage of seminiferous tubule cross-sections containing spermatogonia) and the number of spermatogonia per seminiferous tubule cross-section (S/T). All studies have demonstrated that TFI and S/T always decrease after the introduction of chemotherapeutic agents, especially those which carry high gonadotoxic risks such as alkylating agents. STUDY DESIGN, SIZE, DURATION: Testicular tissue samples from 79 (pre)pubertal boys diagnosed with cancer (from 6 months to 16 years of age) were cryopreserved between May 2009 and June 2014. Their medical diagnoses and previous chemotherapy exposures were recorded. We examined histological sections of (pre)pubertal testicular tissue to elucidate whether the chemotherapy or the primary diagnosis affects mainly TFI and S/T. PARTICIPANTS/MATERIALS, SETTING, METHODS: (Pre)pubertal boys with cancer diagnosis who had been offered TTF prior to conditioning treatment for hematopoietic stem cell transplantation were included in the study. All the patients had previously received chemotherapy with low- or moderate-risk for future fertility. We have selected patients for whom the information on the chemotherapy received was complete. The quantity of spermatogonia and quality of testicular tissue were assessed by both morphological and immunohistochemical analyses. MAIN RESULTS AND THE ROLE OF CHANCE: A significant reduction in the number of spermatogonia was observed in boys treated with alkylating agents. The mean S/T values in boys exposed to alkylating agents were significantly lower compared to boys exposed to non-alkylating agents (P = 0.018). In contrast, no difference was observed for patients treated with carboplatin as the sole administered alkylating agent compared to the group of patients exposed to non-alkylating agents. We observed an increase of S/T with age in the group of patients who did not receive any alkylating agent and a decrease of S/T with age when patients received alkylating agents included in the cyclophosphamide equivalent dose (CED) formula (r = 0.6166, P = 0.0434; r = -0.3759, P = 0.0036, respectively). The TFI and S/T decreased further in the group of patients who received vincristine in combination with alkylating agents (decrease of 22.4%, P = 0.0049 and P < 0.0001, respectively), but in this group the CED was also increased significantly (P < 0.0001). Multivariate analysis, after CED adjustment, showed the persistence of a decrease in TFI correlated with vincristine administration (P = 0.02). LIMITATIONS, REASONS FOR CAUTION: This is a descriptive study of testicular tissues obtained from (pre)pubertal boys who were at risk of infertility. The study population is quite heterogeneous, with a small number of patients in each sub-group. Our results are based on comparisons between patients receiving alkylating agents compared to patients receiving non-alkylating agents rather than chemotherapy-naive patients. The French national guidelines for fertility preservation in cancer patients recommend TTF before highly gonadotoxic treatment. Therefore, all the patients had received low- or moderate-risk gonadotoxic chemotherapy before TTF. Access to testicular tissue samples from chemotherapy-naive patients with comparable histological types of cancer was not possible. The functionality of spermatogonia and somatic cells could not be tested by transplantation or in vitro maturation due to limited sample sizes. WIDER IMPLICATIONS OF THE FINDINGS: This study summarizes the spermatogonial quantity of (pre)pubertal boys prior to TTF. We confirmed a negative correlation between the cumulative exposure to alkylating agents and spermatogonial quantity. In addition, the synergistic use of vincristine in combination with alkylating agents showed a cumulative deleterious effect on the TFI. For patients for whom fertility preservation is indicated, TTF should be proposed for chemotherapy with a predicted CED above 4000 mg/m2. However, the data obtained from vincristine and carboplatin use should be confirmed in a subsequent study including more patients. STUDY FUNDING/COMPETING INTEREST(S): This study had financial support from a French national research grant PHRC No. 2008/071/HP obtained by the French Institute of Cancer and the French Healthcare Organization. The sponsors played no role in the study. The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Feraille A, Liard A, Rives N, et al. Impact of low- or moderate-risk gonadotoxic chemotherapy prior to testicular tissue freezing on spermatogonia quantity in human (pre)pubertal testicular tissue. Hum Reprod. 2023. PMID: 37674325. doi:10.1093/humrep/dead161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。